Articles published by Viridian Therapeutics, Inc.
![](https://mms.businesswire.com/media/20240805076289/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240807247885/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240725241981/en/2003056/5/Viridian_Logo_-_Jan.jpg)
![](https://mms.businesswire.com/media/20240703993817/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240611897132/en/2003056/5/Viridian_Logo_-_Jan.jpg)
![](https://mms.businesswire.com/media/20240606422492/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240531086999/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240510199739/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240508566867/en/2003056/5/Viridian_Logo_-_Jan.jpg)
![](https://mms.businesswire.com/media/20240502119093/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240428139202/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240404065547/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240306688390/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240305448281/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240227846012/en/2003056/5/Viridian_Logo_-_Jan.jpg)
![](https://mms.businesswire.com/media/20240215293347/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240206666436/en/2003056/5/Viridian_Logo_-_Jan.jpg)
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240117318433/en/2002443/22/Viridian_Logo.jpg)
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240115733377/en/1999389/22/Viridian_Logo.jpg)
![](https://mms.businesswire.com/media/20240108920225/en/1991478/22/Viridian_Logo.jpg)
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20240104648163/en/1988007/5/Viridian_Logo.jpg)
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
Via Business Wire
Tickers
VRDN
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20231121247074/en/1925751/5/Viridian_Logo1_%281%29.jpg)
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20231113537474/en/1925751/5/Viridian_Logo1_%281%29.jpg)
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20231108658074/en/1925751/5/Viridian_Logo1_%281%29.jpg)
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
November 08, 2023
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20231103220943/en/1925751/5/Viridian_Logo1_%281%29.jpg)
![](https://mms.businesswire.com/media/20231030739786/en/1925751/5/Viridian_Logo1_%281%29.jpg)
![](https://mms.businesswire.com/media/20231026854999/en/1925739/5/Viridian_Logo1_%281%29.jpg)
![](https://mms.businesswire.com/media/20230925962260/en/1897298/5/Viridian_Logo1.jpg)
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
September 25, 2023
Via Business Wire
Tickers
VRDN
![](https://mms.businesswire.com/media/20230907907028/en/1883388/5/Viridian_Logo1.jpg)
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
September 07, 2023
Via Business Wire
Tickers
VRDN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.